Here's an example of an oncology drug (prostate) that was recently fast tracked by the FDA.
It was stopped mid phase 3. It demonstrated a 4.8 month median OS benefit and 5.4mnth PFS. This is a lower benefit than I would have thought to stop the trial early, but due to it's low toxicity it was approved.
http://www.clinicalleader.com/doc.mvc/xtandi-gets-speedy-fda-ok-metastatic-castration-prostate-cancer-0001
benefits of priority review and orphan status
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 36.0¢ | 34.5¢ | $443.7K | 1.252M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 25847 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 275675 | 28 |
View Market Depth
| Last trade - 13.33pm 19/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |